March 31 (Reuters) - Britain's Competition and Markets Authority (CMA) said on Friday that it would refer UnitedHealth Group's planned acquisition of healthcare technology firm EMIS for a Phase 2 investigation.
The watchdog said it had rejected remedies offered by U.S.-based UnitedHealth after deeming they did not go far enough in mitigating the potential competitive impact of the combination. (Reporting by Pablo Mayo Cerqueiro; editing by Jason Neely)